Jay Olson is a stage magician and psychology researcher at University of Toronto. Given his unique background, he was ...

The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, today announced topline int ...

The FCM protein snack bar, rich in amino acids and antioxidants, improves brain function and memory accuracy in just six ...

Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024Participant ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP ® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance ...

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for ...

Part 1 was an open-label pilot study, comparing HLX14’s pharmacokinetics with EU-sourced PROLIA after subcutaneous injection, setting the foundation for Part 2. Part 2 was a double-blind, four-arm ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...